Bulk Pharmaceutical API Sources for HYZAAR

Bulk Pharmaceutical API Sources for HYZAAR

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		3961
MolPort		MolPort-003-666-553
ISpharm		I14-9710
ABI Chem		AC1L1H3Q
ChemMol		49409096
Amadis Chemical		A803239
BioChemPartner		BCPP000183

Bulk Active Pharmaceutical Ingredient (API) Sources for HYZAAR

Last updated: August 4, 2025

---

Introduction

HYZAAR is a combination medication containing olmesartan medoxomil and hydrochlorothiazide, primarily prescribed for managing hypertension and reducing the risk of cardiovascular events. The active pharmaceutical ingredients (APIs)—olmesartan medoxomil (an angiotensin receptor blocker) and hydrochlorothiazide (a diuretic)—are produced by specialized bulk API manufacturers. The quality and reliability of these API sources are critical for ensuring medication efficacy, regulatory compliance, and supply chain stability.

This report provides a comprehensive overview of the global bulk API suppliers for HYZAAR, highlighting key manufacturing regions, industry-leading companies, and considerations for procurement strategies.

---

Global API Manufacturing Landscape for HYZAAR

The production of olmesartan medoxomil and hydrochlorothiazide involves complex chemical synthesis and stringent quality control. Leading pharmaceutical ingredient manufacturers operate primarily within North America, Europe, and Asia, notably India and China, which host a significant share of the global API manufacturing capacity. These regions are favored due to their advanced chemical manufacturing expertise, cost competitiveness, and regulatory compliance standards.

---

API Suppliers for Olmesartan Medoxomil

1. Teva Pharmaceutical Industries Ltd.

• Overview: An Israeli multinational, Teva is a prominent producer of generic APIs and finished pharmaceuticals.
• Strengths: Extensive manufacturing facilities in Europe and India; proven global supply chain.
• Regulatory Status: ISO-certified and compliant with GMP standards, facilitating worldwide distribution.

2. Sun Pharmaceutical Industries Ltd.

• Overview: An Indian pharmaceutical giant with significant API production capacity.
• Strengths: Specializes in high-volume synthesis of ARB APIs, including olmesartan.
• Regulatory Compliance: Good Manufacturing Practices (GMP) adherence, with approvals from multiple regulatory authorities.

3. Zhejiang Huahai Pharmaceutical Co., Ltd.

• Overview: Based in China, Huahai is a major supplier of ARBs, including olmesartan medoxomil.
• Strengths: Large-scale production and ongoing investments in API quality enhancements.
• Regulatory Status: Subject to regulatory scrutiny, with recent focus on GMP audits, emphasizing the importance of compliance.

4. Accord Healthcare and Other Indian API Manufacturers

Indian firms like Natco Pharma and Aurobindo Pharma also produce olmesartan APIs, supporting both branded and generic formulations globally.

---

API Suppliers for Hydrochlorothiazide

1. Prasco Laboratories

• Overview: A US-based API supplier and manufacturer, providing high-quality hydrochlorothiazide.
• Strengths: ISO and cGMP compliance, focusing on the North American market.
• Regulatory Status: Strong adherence to US FDA standards.

2. Zhejiang Hisun Pharmaceutical Co., Ltd.

• Overview: Chinese manufacturer with a broad portfolio of diuretics, including hydrochlorothiazide.
• Strengths: Cost-effectiveness and large API capacity.
• Regulatory Consideration: Must ensure vendor compliance with current Good Manufacturing Practices (cGMP) for regulatory acceptance.

3. Hetero Labs Limited

• Overview: Indian pharmaceutical company specializing in diuretics and cardiovascular APIs.
• Strengths: Proven manufacturing track record and regulatory approvals worldwide.

4. Teva Pharmaceutical Industries Ltd.

• Overview: Also supplies hydrochlorothiazide API with consistent quality standards as part of its broad API portfolio.

---

Considerations for Selecting API Suppliers

Quality and Regulatory Compliance:
Suppliers should have current cGMP certifications, recent regulatory audits, and quality assurance protocols that align with the standards of major markets like the US (FDA), EU (EMA), and Japan (PMDA).

Supply Chain Reliability:
Manufacturers with multiple facilities across regions, especially those with dedicated API production lines and contingency plans, offer more resilient supply chain options.

Cost and Lead Times:
While Chinese and Indian suppliers often provide competitive pricing due to lower manufacturing costs, it is critical to evaluate lead times, regulatory approval status, and quality consistency.

Traceability and Documentation:
Transparent documentation of manufacturing processes, Certificates of Analysis (CoA), batch records, and compliance history are non-negotiable in API sourcing.

---

Regulatory and Quality Assurance Challenges

The sourcing of APIs for drugs like HYZAAR, which are legend- or prescription-only medications, demands strict adherence to regulatory standards. Suppliers must demonstrate compliance with cGMP, undergo regular audits, and provide comprehensive documentation to support regulatory filings and inspections. Recent scrutiny on Chinese and Indian API manufacturers' GMP compliance highlights the need for rigorous supplier evaluation.

Furthermore, quality issues such as impurities or deviations from specifications can compromise product efficacy and safety, resulting in regulatory actions or supply disruptions. Selecting API sources with proven quality records mitigates such risks.

---

Strategic Approaches to API Sourcing for HYZAAR

Diversified Supplier Base:
Engaging multiple reputable suppliers across different regions reduces dependency on a single source, diminishes risk, and enables negotiation leverage.

Long-Term Partnerships:
Establishing strategic alliances with key suppliers ensures priority access to APIs, especially during market fluctuations or supply chain disruptions.

API Validation and Lot Testing:
Implementing rigorous incoming inspection protocols and batch testing ensures API batch consistency, supporting regulatory compliance and product efficacy.

Monitoring and Compliance:
Tracking regulatory updates, GMP audit reports, and supplier certifications helps maintain supply chain integrity.

---

Conclusion

The global API landscape for HYZAAR’s constituents, olmesartan medoxomil and hydrochlorothiazide, is characterized by a mix of established international API producers primarily based in India, China, and North America. Selecting the right suppliers hinges on a careful assessment of quality standards, regulatory compliance, supply reliability, and cost considerations. Ensuring traceability and validating supplier capabilities are essential steps for pharmaceutical companies aiming to maintain consistent, high-quality production of HYZAAR.

---

Key Takeaways

• Diverse API sourcing is crucial to mitigate risks associated with regional manufacturing disruptions.
• Regulatory compliance (cGMP adherence, recent audits) remains the foremost criterion for API supplier selection.
• Top global API manufacturers for olmesartan include Teva, Sun Pharma, Zhejiang Huahai, and Accord, while hydrochlorothiazide is supplied by companies like Hetero Labs and Zhejiang Hisun.
• Strategic supplier relationships and transparent documentation underpin successful API procurement.
• Regulatory vigilance is vital amidst evolving GMP standards and regional oversight.

---

FAQs

Q1: How do I verify the regulatory compliance of an API manufacturer?
A: Verify certifications such as cGMP, inspect recent regulatory audit reports, and review past compliance records with agencies like the FDA, EMA, or PMDA.

Q2: What are the risks of sourcing APIs from China or India?
A: Potential risks include inconsistent quality, regulatory non-compliance, and supply chain disruptions. Due diligence and periodic audits mitigate these concerns.

Q3: How can I ensure API quality consistency over multiple batches?
A: Implement strict incoming quality control testing, require Certificates of Analysis, and validate each batch against specifications.

Q4: Are there any exclusive API manufacturers for HYZAAR?
A: No. Multiple manufacturers produce olmesartan medoxomil and hydrochlorothiazide, providing redundancy and flexibility.

Q5: What impact do quality issues in API production have on HYZAAR?
A: Quality issues can compromise drug safety, efficacy, and regulatory compliance, potentially leading to recalls or market withdrawals.

---

Sources

1. [1] Teva Pharmaceuticals: Product Portfolio and Quality Standards
2. [2] Sun Pharmaceutical: API Manufacturing Capabilities
3. [3] Zhejiang Huahai Pharmaceutical: Regulatory and Quality Information
4. [4] US FDA Database: API Manufacturer Approvals
5. [5] Industry Reports on API Supply Chain and Global Manufacturing Trends